Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noel Clarke

Showing results (1-10 of 82) with videos related to

Pageof 9
Sort By:
The Lancet. Oncology|September 8, 2018
Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer? - Authors' replyNoel Clarke
European Urology|March 30, 2011
Targeted caval cytoreduction: solid foundations or shifting sands?Axel Bex, Noel Clarke
European Urology|March 1, 2008
Open to debate. The Motion: all men over the age of 50 should be encouraged to take a 5alpha-reductase inhibitor to prevent prostate cancerLaurence Koltz, Noel Clarke
European Urology|January 25, 2006
Natural history and treatment of bone complications in prostate cancerFred Saad, Noel Clarke, Marc Colombel
European Urology|December 25, 2009
Re: Umberto Capitanio, Shahrokh F. Shariat, Hendrik Isbarn, et al. Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol 2009;56:1-9Joan Palou, Óscar Rodríguez, Noel Clarke
BJUI Compass|June 30, 2026
Retroperitoneal lymph-node dissection for isolated nodal recurrence of renal cell carcinoma after nephrectomy: Contemporary outcomes of a case seriesAlberto Costa Silva, Noel Clarke, Aziz Gulamhusein
European Urology|June 20, 2019
Re: David W. Donnelly, Anna Gavin, Amy Downing, et al. Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom. Eur Urol 2019;76:228-37Noel Clarke, Heather Payne, Jan van der Meulen
BJU International|January 8, 2010
Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancerRoger S Kirby, John M Fitzpatrick, Noel Clarke
Biochemical and Biophysical Research Communications|February 28, 2016
Stroma-induced Jagged1 expression drives PC3 prostate cancer cell migration; disparate effects of RIP-generated proteolytic fragments on cell behaviour and Notch signalingCraig Delury, Claire Hart, Mick Brown, et al.
Urologic Oncology|July 5, 2015
Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanismsÅsa Tivesten, Jehonathan H Pinthus, Noel Clarke, et al.
Pageof 9

Showing results (1-10 of 82) with videos related to

Sort By:
Pageof 9
The Lancet. Oncology|September 8, 2018
Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer? - Authors' replyNoel Clarke
European Urology|March 30, 2011
Targeted caval cytoreduction: solid foundations or shifting sands?Axel Bex, Noel Clarke
European Urology|March 1, 2008
Open to debate. The Motion: all men over the age of 50 should be encouraged to take a 5alpha-reductase inhibitor to prevent prostate cancerLaurence Koltz, Noel Clarke
European Urology|January 25, 2006
Natural history and treatment of bone complications in prostate cancerFred Saad, Noel Clarke, Marc Colombel
European Urology|December 25, 2009
Re: Umberto Capitanio, Shahrokh F. Shariat, Hendrik Isbarn, et al. Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol 2009;56:1-9Joan Palou, Óscar Rodríguez, Noel Clarke
BJUI Compass|June 30, 2026
Retroperitoneal lymph-node dissection for isolated nodal recurrence of renal cell carcinoma after nephrectomy: Contemporary outcomes of a case seriesAlberto Costa Silva, Noel Clarke, Aziz Gulamhusein
European Urology|June 20, 2019
Re: David W. Donnelly, Anna Gavin, Amy Downing, et al. Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom. Eur Urol 2019;76:228-37Noel Clarke, Heather Payne, Jan van der Meulen
BJU International|January 8, 2010
Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancerRoger S Kirby, John M Fitzpatrick, Noel Clarke
Biochemical and Biophysical Research Communications|February 28, 2016
Stroma-induced Jagged1 expression drives PC3 prostate cancer cell migration; disparate effects of RIP-generated proteolytic fragments on cell behaviour and Notch signalingCraig Delury, Claire Hart, Mick Brown, et al.
Urologic Oncology|July 5, 2015
Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanismsÅsa Tivesten, Jehonathan H Pinthus, Noel Clarke, et al.
Pageof 9